Sein métastatique RH+
COMPLEEMENT-1
An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease.
Paris, Saint-Cloud
PAUL-HENRI COTTU, FLORENCE LEREBOURS
Sein métastatique RH+
PADA-1
Randomized, Open Label, Multicentric Phase III Trial to Evaluate the Safety and Efficacy of Palbociclib in Combination With HTdriven by ctDNA ESR1 Mutation Monitoring in ER+, HER2-negative Metastatic Breast Cancer Patients.
Paris, Saint-Cloud
FRANCOIS-CLEMENT BIDARD, CORALINE DUBOT
Sein métastatique RH+
EMERALD
ELACESTRANT MONOTHERAPY VS. STANDARD OF CARE FOR THE TREATMENT OF PATIENTS WITH ER+/HER2- ADVANCED BREAST CANCER FOLLOWING CDK4/6 INHIBITOR THERAPY: A PHASE 3 RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, MULTICENTER TRIAL
Paris, Saint-Cloud
Appareil Digestif
AAS-Lynch
Assessment of the Effect of a Daily Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch Syndrome
Paris, Saint-Cloud
BRUNO BUECHER
Appareil Digestif
ADAGE - Prodige 34
Randomised Phase III Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over.
Saint-Cloud
Sein métastatique RH+
AMBRE
OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE III STUDY, COMPARING;STANDARD CHEMOTHERAPY TO ENDOCRINE THERAPY + ABEMACICLIB;COMBINATION AS INITIAL METASTATIC TREATMENT AMONG PATIENTS WITH;VISCERAL METASTASIS OF ER+ HER2- BREAST CANCER, HIGH BURDEN;DISEASE
Paris, Saint-Cloud
FRANCOIS-CLEMENT BIDARD, FRANCOIS-CLEMENT BIDARD
Sein métastatique RH+
CONTESSA - ODO-TE-B301
Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
Saint-Cloud
ETIENNE BRAIN
Sein métastatique RH+
DESTINY-Breast06 (D9670C00001)
TITLE PAGE;A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus InvestigatorÀs Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06)
Paris, Saint-Cloud
JEAN-YVES PIERGA, ETIENNE BRAIN
Appareil Digestif
EPIC 1511
Impact of Early Palliative Care on Overall Survival of Patients With Metastatic Upper Gastrointestinal Cancers, Treated With First-line Chemotherapy: a Randomized Phase III Trial.
Saint-Cloud
ELISABETH ANGELLIER